BRPI1009860A8 - composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais - Google Patents

composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais Download PDF

Info

Publication number
BRPI1009860A8
BRPI1009860A8 BRPI1009860A BRPI1009860A BRPI1009860A8 BR PI1009860 A8 BRPI1009860 A8 BR PI1009860A8 BR PI1009860 A BRPI1009860 A BR PI1009860A BR PI1009860 A BRPI1009860 A BR PI1009860A BR PI1009860 A8 BRPI1009860 A8 BR PI1009860A8
Authority
BR
Brazil
Prior art keywords
diseases
prevention
compound
humans
animals
Prior art date
Application number
BRPI1009860A
Other languages
English (en)
Inventor
Marcilla Etxenike Amaia
Horacio López Daniel
Barceló Coblijn Gwendolyn
Laura Martín María
Higuera Urbano Mónica
Vicente Escribá Ruiz Pablo
Álvarez Martínez Rafael
Terés Jiménez Silvia
Lladó Cañellas Victoria
Busquets Xaubet Xavier
Original Assignee
Lipopharma Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopharma Therapeutics S L filed Critical Lipopharma Therapeutics S L
Publication of BRPI1009860A2 publication Critical patent/BRPI1009860A2/pt
Publication of BRPI1009860A8 publication Critical patent/BRPI1009860A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

uso de um composto e composição farmacêutica ou nutracêutica uso de derivados poli-insaturados de ácido graxo como medicamentos ou alimentos funcionais. a presente invenção refere-se ao uso de derivados de ácido graxo 1,2 para o tratamento ou a prevenção de doenças comuns cuja etiologia seja baseada em alterações (de qualquer tipo) nos lipídios da membrana celular, por exemplo, alterações nos níveis, na composição ou na estrutura desses lipídios. além disso, para doenças nas quais a regulação da composição do lipídio e da estrutura das membranas (ou das proteínas que interagem com as membranas) cause a reversão do estado patológico.
BRPI1009860A 2009-03-16 2010-03-15 composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais BRPI1009860A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200900725A ES2345241B1 (es) 2009-03-16 2009-03-16 Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
PCT/ES2010/070153 WO2010106211A1 (es) 2009-03-16 2010-03-15 Uso de derivados de ácidos grasos poliinsaturados como medicamentos

Publications (2)

Publication Number Publication Date
BRPI1009860A2 BRPI1009860A2 (pt) 2016-03-08
BRPI1009860A8 true BRPI1009860A8 (pt) 2019-12-17

Family

ID=42673244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009860A BRPI1009860A8 (pt) 2009-03-16 2010-03-15 composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais

Country Status (18)

Country Link
US (7) US9161928B2 (pt)
EP (2) EP2409963B1 (pt)
JP (1) JP5904592B2 (pt)
KR (4) KR20180021931A (pt)
CN (4) CN109999018A (pt)
AU (6) AU2010224749B2 (pt)
BR (1) BRPI1009860A8 (pt)
CA (1) CA2754963C (pt)
CL (1) CL2011002268A1 (pt)
DK (2) DK3159329T3 (pt)
ES (3) ES2345241B1 (pt)
HU (2) HUE032027T2 (pt)
MX (1) MX2011009614A (pt)
PL (1) PL2409963T3 (pt)
PT (2) PT2409963T (pt)
RU (1) RU2513995C2 (pt)
SI (1) SI3159329T1 (pt)
WO (1) WO2010106211A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
KR102110200B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 산화성 망막 질환
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
ES2401629B1 (es) 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
CA2965047C (en) * 2014-10-21 2018-06-26 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
JP6569919B2 (ja) * 2015-03-06 2019-09-04 国立大学法人 新潟大学 レビー小体型認知症のバイオマーカー
CN108698987B (zh) 2015-11-23 2021-07-13 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
EP4234035A3 (en) 2017-05-16 2023-11-15 Ability Pharmaceuticals S.A. A pharmaceutical combination for the treatment of a cancer
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
JP7736313B2 (ja) * 2020-01-29 2025-09-09 ウニバシタット デ レス イレス バレアース αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
AU2021220258A1 (en) 2020-02-10 2022-06-30 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
KR20260018193A (ko) 2020-02-21 2026-02-06 레트로토프 인코포레이티드 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717816D0 (en) 1987-07-28 1987-09-03 Manchester Inst Science Tech Fabric testing apparatus
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) * 1991-06-21 1993-01-08 Sagami Chem Res Center ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) * 1999-06-29 2002-07-01 Consejo Superior Investigacion Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en) * 2000-07-20 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) * 2001-02-12 2002-08-29 Celanese Ventures Gmbh Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
WO2003084305A2 (en) * 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2008520739A (ja) * 2004-11-19 2008-06-19 マーテック・バイオサイエンシーズ・コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
EP1888728A4 (en) * 2005-05-04 2010-07-14 Pronova Biopharma Norge As Fatty acid analogues, D.H. DHA DERIVATIVES FOR USE AS A MEDICAMENT
US8059805B2 (en) * 2005-06-30 2011-11-15 Emc Corporation Enhanced services provided using communication redirection and processing
RU2444356C2 (ru) 2005-07-08 2012-03-10 Мартек Байосайенсиз Корпорейшн Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
PL1800675T4 (pl) * 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
JP2010508262A (ja) 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
JP5552313B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

Also Published As

Publication number Publication date
AU2020205213B2 (en) 2021-02-25
BRPI1009860A2 (pt) 2016-03-08
US11253497B2 (en) 2022-02-22
RU2011141850A (ru) 2013-04-27
EP2409963B1 (en) 2017-01-04
ES2345241A1 (es) 2010-09-17
US20200352891A1 (en) 2020-11-12
EP3159329A1 (en) 2017-04-26
KR101833772B1 (ko) 2018-03-02
ES2613606T3 (es) 2017-05-24
AU2020205213A1 (en) 2020-07-30
AU2018203976A1 (en) 2018-06-21
US20120108550A1 (en) 2012-05-03
US20160158180A1 (en) 2016-06-09
US10201515B2 (en) 2019-02-12
CA2754963C (en) 2022-02-08
AU2020205214A1 (en) 2020-07-30
JP5904592B2 (ja) 2016-04-13
CN106420686B (zh) 2020-05-22
HUE051850T2 (hu) 2021-03-29
EP3159329B1 (en) 2020-08-12
CN109999018A (zh) 2019-07-12
AU2016238970B2 (en) 2018-03-08
AU2020205214B2 (en) 2021-02-18
KR20180021931A (ko) 2018-03-05
US9907772B2 (en) 2018-03-06
SI3159329T1 (sl) 2021-01-29
AU2019226257A1 (en) 2019-09-26
CN106349058A (zh) 2017-01-25
EP2409963A1 (en) 2012-01-25
ES2345241B1 (es) 2011-09-08
AU2019226257B2 (en) 2020-05-07
AU2018203976B2 (en) 2019-06-06
US20190365690A1 (en) 2019-12-05
RU2513995C2 (ru) 2014-04-27
CA2754963A1 (en) 2010-09-23
PT3159329T (pt) 2020-11-13
CN102356057A (zh) 2012-02-15
HK1232207A1 (zh) 2018-01-05
KR20200024953A (ko) 2020-03-09
US9763906B2 (en) 2017-09-19
US20180085332A1 (en) 2018-03-29
CN106420686A (zh) 2017-02-22
ES2820025T3 (es) 2021-04-19
DK2409963T3 (en) 2017-02-27
HUE032027T2 (en) 2017-08-28
PL2409963T3 (pl) 2017-05-31
MX2011009614A (es) 2012-01-20
US9763907B2 (en) 2017-09-19
AU2010224749A1 (en) 2011-10-13
US20170035720A1 (en) 2017-02-09
US9161928B2 (en) 2015-10-20
WO2010106211A1 (es) 2010-09-23
KR20190018754A (ko) 2019-02-25
AU2010224749B2 (en) 2016-07-07
PT2409963T (pt) 2017-02-15
KR102233102B1 (ko) 2021-03-26
KR20110137365A (ko) 2011-12-22
JP2012520344A (ja) 2012-09-06
AU2016238970A1 (en) 2016-11-03
US20160158181A1 (en) 2016-06-09
EP2409963A4 (en) 2013-10-02
DK3159329T3 (da) 2020-11-09
CN106349058B (zh) 2020-01-14
CL2011002268A1 (es) 2012-01-27

Similar Documents

Publication Publication Date Title
BR112015009975A2 (pt) métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal
BR112015018479A2 (pt) composições nutricionais contendo glóbulos de gordura estruturados e seus usos
BR112015018411A2 (pt) composições nutritivas contendo uma fração lipídica enriquecida e usos destas
BR112013026661A2 (pt) método de entrega de vacina
BR112012030337A2 (pt) vacinas compreendendo colesterol e cpg como moléculas veículo-adjuvante exclusivas e uso das mesmas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112013018539A2 (pt) Novas fucosil transferases e suas aplicações
BR112014008511A2 (pt) composições nutricionais com fitonutrientes
BR112015022936A2 (pt) vesículas de colestossoma para a incorporação de moléculas em quilomícrons
BRPI0802241A2 (pt) células-tronco mesenquimais e seus usos
CL2011002268A1 (es) Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.
BR112014001291A2 (pt) dispositivos médicos com garras giratórias destacáveis
BR112017009678A2 (pt) composição optimizada de nutrientes de ácidos graxos e método de preparação da mesma
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BR112014012808A2 (pt) proteína de fusão anticâncer
BR112014019927A8 (pt) fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente
BR112018000236A2 (pt) composições nutricionais e métodos para a promoção do desenvolvimento cognitivo
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112018013292A2 (pt) ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii?
BR112012000115B8 (pt) composição compreendendo aminoácidos e/ou peptídeos bioativos e óleo marinho em uma emulsão óleo-em-água estável, processo para a produção e seus usos
BR112014008512A2 (pt) composições nutricionais de caseína-soro de leite parcialmente hidrolizadas para redução do início de alergias
BR112014005398A2 (pt) peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmo
BR112015032572A2 (pt) composições e métodos para melhorar o desempenho durante exercícios
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
BR112014027738A2 (pt) ácido graxo de talóleo que é modificado por saponificação para uso, suplemento alimentar, e composto alimentar

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]